Work

Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.

Year: 2012

Type: article

Abstract: Despite the use of aggressive trimodality therapy consisting of neoadjuvant chemotherapy, surgery, and hemithoracic radiation, the median survival of patients with malignant pleural mesothelioma (MPM) is 12 to 18 months (1,2). Immune responses have been shown to be beneficial in MPM patients (3,4); therefore, focusing immunotherapeutic strategies on promoting these immune responses is an attractive approach. One such approach involves targeting cancer-associated antigens highly expressed on mesothelioma cells by use of monoclonal antibodies, recombinant immunotoxins, vaccines, or genetically engineered T cells. Targeted antigens can be either cell-surface antigens, such as mesothelin, or intracellular antigens, such as WT-1. Cell-surface antigens are favored for the immunotherapeutic approach because of their ease of targeting.

Source: PubMed

DOI: 10.3978/j.issn.2225-319x.2012.10.03

Authors: Jonathan Villena-Vargas, Prasad S Adusumilli

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Occupational and environmental lung diseases

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute